Loading...
XETRT5O
Market cap777kUSD
Sep 02, Last price  
1.45EUR
Name

bioXXmed AG

Chart & Performance

D1W1MN
XETR:T5O chart
P/E
—
P/S
42.80
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.18%
Rev. gr., 5y
76.68%
Revenues
17k
+42.27%
50,00050,00050,00050,00050,000300,4940089,8201,01136,18136,00044,62612,23317,404
Net income
-21m
00-822,51100000000000-20,949,130
CFO
0k
-865,000-1,403,000-428,000-699,000-895,000-926,000-1,496,000-952,000-1,147,000-1,262,000-911,000-1,658,000000

Profile

CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company's therapies include proprietary small molecules and biologics to provide treatment options in dermatology, cardiology and angiology, urology, and oncology. Its lead clinical product is DermaPro that has completed Phase III clinical trials for the treatment of diabetic foot ulcers in India; is in Phase III clinical trials for diabetic foot ulcer treatment in Europe; and is in Phase II/III clinical studies for the treatment of venous leg ulcers in Germany, as well as is used as an anti-infective. The company also develops Utisept, an urological medical device for flushing the bladder in urinary tract infections; Derma MP for the treatment of venous leg ulcers in Europe; CardioClean that is in preclinical stage for the treatment of restenosis, diabetis, and carotis-stenosis; and Cancer T17-n for cancer treatment in Europe. CytoTools has collaboration agreement with Activoris Medizintechnik GmbH to develop inhalation therapy for viral infections, such as COVID-19 and influenza. CytoTools AG was founded in 2000 and is based in Darmstadt, Germany.
URL
https://bioxxmed.ag/
IPO date
May 18, 2007
Employees
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
17
42.27%
12
-72.59%
45
23.96%
Cost of revenue
541
Unusual Expense (Income)
NOPBT
17
12
(496)
NOPBT Margin
100.00%
100.00%
Operating Taxes
35
40
Tax Rate
284.57%
NOPAT
17
(23)
(536)
Net income
(20,949)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
4,383
BB yield
Debt
Debt current
122
Long-term debt
122
Deferred revenue
Other long-term liabilities
54
105
Net debt
(613)
(21,494)
(17,910)
Cash flow
Cash from operating activities
CAPEX
(140)
Cash from investing activities
(504)
(1,469)
Cash from financing activities
4,219
FCF
87
(100)
(473)
Balance
Cash
613
1,840
Long term investments
2
19,654
18,154
Excess cash
612
21,493
18,151
Stockholders' equity
(36,923)
5,575
4,465
Invested Capital
37,455
15,949
13,650
ROIC
0.07%
ROCE
3.27%
0.06%
EV
Common stock shares outstanding
5,137
4,966
3,973
Price
Market cap
EV
EBITDA
20,220
12
2,053
EV/EBITDA
Interest
42
Interest/NOPBT
340.49%